Annual Accounts Receivable
$5.27 M
+$686.00 K+14.96%
December 31, 2023
Summary
- As of February 8, 2025, PLX annual accounts receivable is $5.27 million, with the most recent change of +$686.00 thousand (+14.96%) on December 31, 2023.
- During the last 3 years, PLX annual accounts receivable has risen by +$3.27 million (+163.60%).
- PLX annual accounts receivable is now -42.97% below its all-time high of $9.24 million, reached on December 31, 2010.
Performance
PLX Accounts Receivable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Accounts Receivable
$2.19 M
-$7.93 M-78.32%
September 30, 2024
Summary
- As of February 8, 2025, PLX quarterly accounts receivable is $2.19 million, with the most recent change of -$7.93 million (-78.32%) on September 30, 2024.
- Over the past year, PLX quarterly accounts receivable has dropped by -$6.74 million (-75.43%).
- PLX quarterly accounts receivable is now -79.91% below its all-time high of $10.93 million, reached on March 31, 2011.
Performance
PLX Quarterly Accounts Receivable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Accounts Receivable Formula
Accounts Receivable = Total Credit Sales − Amount Collected from Credit Sales
PLX Accounts Receivable Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +15.0% | -75.4% |
| 3 y3 years | +163.6% | -75.4% |
| 5 y5 years | +11.5% | -75.4% |
PLX Accounts Receivable Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | at high | +53.2% | -78.3% | +68.3% |
| 5 y | 5-year | at high | +163.6% | -78.3% | +68.3% |
| alltime | all time | -43.0% | +1975.6% | -79.9% | +764.2% |
Protalix BioTherapeutics Accounts Receivable History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2024 | - | $2.19 M(-78.3%) |
| Jun 2024 | - | $10.13 M(+169.4%) |
| Mar 2024 | - | $3.76 M(-28.7%) |
| Dec 2023 | $5.27 M(+15.0%) | $5.27 M(-41.0%) |
| Sep 2023 | - | $8.94 M(+120.7%) |
| Jun 2023 | - | $4.05 M(+210.5%) |
| Mar 2023 | - | $1.30 M(-71.6%) |
| Dec 2022 | $4.59 M(+33.2%) | $4.59 M(-47.0%) |
| Sep 2022 | - | $8.65 M(+327.8%) |
| Jun 2022 | - | $2.02 M(-65.8%) |
| Mar 2022 | - | $5.91 M(+71.6%) |
| Dec 2021 | $3.44 M(+72.1%) | $3.44 M(-38.1%) |
| Sep 2021 | - | $5.56 M(+138.7%) |
| Jun 2021 | - | $2.33 M(-49.3%) |
| Mar 2021 | - | $4.60 M(+130.0%) |
| Dec 2020 | $2.00 M(-57.4%) | $2.00 M(-36.4%) |
| Sep 2020 | - | $3.15 M(-40.2%) |
| Jun 2020 | - | $5.26 M(-40.7%) |
| Mar 2020 | - | $8.88 M(+88.9%) |
| Dec 2019 | $4.70 M(-0.6%) | $4.70 M(-46.1%) |
| Sep 2019 | - | $8.72 M(+20.1%) |
| Jun 2019 | - | $7.26 M(-15.3%) |
| Mar 2019 | - | $8.56 M(+81.1%) |
| Dec 2018 | $4.73 M(+174.8%) | $4.73 M(-3.4%) |
| Sep 2018 | - | $4.89 M(-6.7%) |
| Jun 2018 | - | $5.25 M(+10.3%) |
| Mar 2018 | - | $4.76 M(+176.4%) |
| Dec 2017 | $1.72 M(+148.3%) | $1.72 M(-76.4%) |
| Sep 2017 | - | $7.29 M(+142.7%) |
| Jun 2017 | - | $3.00 M(+9.8%) |
| Mar 2017 | - | $2.74 M(+294.9%) |
| Dec 2016 | $693.00 K | $693.00 K(-66.9%) |
| Sep 2016 | - | $2.10 M(+40.4%) |
| Jun 2016 | - | $1.49 M(-67.4%) |
| Sep 2015 | - | $4.57 M(+136.2%) |
| Date | Annual | Quarterly |
|---|---|---|
| Jun 2015 | - | $1.94 M(+6.6%) |
| Mar 2015 | - | $1.82 M(-8.8%) |
| Sep 2014 | - | $1.99 M(-5.0%) |
| Jun 2014 | - | $2.10 M(+20.9%) |
| Mar 2014 | - | $1.74 M(-17.0%) |
| Dec 2013 | $2.09 M(+48.3%) | $2.09 M(+1.9%) |
| Sep 2013 | - | $2.05 M(+1.1%) |
| Jun 2013 | - | $2.03 M(+19.6%) |
| Mar 2013 | - | $1.70 M(+20.4%) |
| Dec 2012 | $1.41 M(+2.6%) | $1.41 M(-80.7%) |
| Sep 2012 | - | $7.31 M(+375.7%) |
| Jun 2012 | - | $1.54 M(+88.5%) |
| Mar 2012 | - | $815.00 K(-40.7%) |
| Dec 2011 | $1.37 M(-85.1%) | $1.37 M(-74.0%) |
| Sep 2011 | - | $5.29 M(+207.6%) |
| Jun 2011 | - | $1.72 M(-84.3%) |
| Mar 2011 | - | $10.93 M(+18.2%) |
| Dec 2010 | $9.24 M(+331.2%) | $9.24 M(+3.4%) |
| Sep 2010 | - | $8.94 M(+137.3%) |
| Jun 2010 | - | $3.77 M(+3.9%) |
| Mar 2010 | - | $3.63 M(+69.1%) |
| Dec 2009 | $2.14 M(+170.4%) | $2.14 M(-20.1%) |
| Sep 2009 | - | $2.68 M(+38.0%) |
| Jun 2009 | - | $1.95 M(-18.6%) |
| Mar 2009 | - | $2.39 M(+201.4%) |
| Dec 2008 | $793.00 K(-41.4%) | $793.00 K(-72.8%) |
| Sep 2008 | - | $2.91 M(+51.7%) |
| Jun 2008 | - | $1.92 M(-8.4%) |
| Mar 2008 | - | $2.10 M(+54.8%) |
| Dec 2007 | $1.35 M(+1.3%) | $1.35 M(-20.3%) |
| Sep 2007 | - | $1.70 M(-25.4%) |
| Jun 2007 | - | $2.28 M(+1.5%) |
| Mar 2007 | - | $2.24 M(+68.0%) |
| Dec 2006 | $1.34 M(+426.0%) | $1.34 M(+426.0%) |
| Dec 2005 | $254.00 K | $254.00 K |
FAQ
- What is Protalix BioTherapeutics annual accounts receivable?
- What is the all time high annual accounts receivable for Protalix BioTherapeutics?
- What is Protalix BioTherapeutics annual accounts receivable year-on-year change?
- What is Protalix BioTherapeutics quarterly accounts receivable?
- What is the all time high quarterly accounts receivable for Protalix BioTherapeutics?
- What is Protalix BioTherapeutics quarterly accounts receivable year-on-year change?
What is Protalix BioTherapeutics annual accounts receivable?
The current annual accounts receivable of PLX is $5.27 M
What is the all time high annual accounts receivable for Protalix BioTherapeutics?
Protalix BioTherapeutics all-time high annual accounts receivable is $9.24 M
What is Protalix BioTherapeutics annual accounts receivable year-on-year change?
Over the past year, PLX annual accounts receivable has changed by +$686.00 K (+14.96%)
What is Protalix BioTherapeutics quarterly accounts receivable?
The current quarterly accounts receivable of PLX is $2.19 M
What is the all time high quarterly accounts receivable for Protalix BioTherapeutics?
Protalix BioTherapeutics all-time high quarterly accounts receivable is $10.93 M
What is Protalix BioTherapeutics quarterly accounts receivable year-on-year change?
Over the past year, PLX quarterly accounts receivable has changed by -$6.74 M (-75.43%)